Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

NCT04817254 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

NIH

Sponsor class

Conditions

Glioblastoma
Gliosarcoma
Malignant Glioma

Interventions

DRUG: TMZ
DRUG: ipilimumab 3mg/kg
DRUG: Nivolumab
DRUG: ipilimumab 1mg/kg

Sponsor

National Cancer Institute (NCI)